9 reports

  • Grindeks, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018
  • Deal Rationale

GlobalData Grindeks, reported one pharmaceuticals & healthcare deal worth $##. ## million in YTD 2018.

  • Healthcare
  • Pharmaceutical
  • Baltics
  • Demand
  • Grindeks RUS, Ltd.
  • 8.3 Rising Healthcare Expenditure Share of the Baltic Countries GDP
  • Baltic Countries - Healthcare Expenditure Share (Percent) of GDP, 2005 - 2015

Table ##-##: Baltic Countries - Healthcare Expenditure Share (Percent) of GDP, 2005 - 2015 ##.

  • Healthcare
  • Therapy
  • Baltics
  • Forecast
  • Market Size

The driving force behind the need for rapid reporting of microbiological test results is the clinical relevance in a time of financial austerity, a time when cost and health care effectiveness to the patient and diagnostician looms ever larger, and where after-the-fact results at high expen

  • Healthcare
  • Infectious Disease
  • Pathology
  • Baltics
  • Northern Europe
  • BIQ PHARMA ACQUIRES RESEARCH FACILITY FROM ASTRAZENECA

GlobalData AstraZeneca AB reported one pharmaceuticals & healthcare deal in YTD 2018.

  • Healthcare
  • Medical Biotechnology
  • Pharmaceutical
  • Baltics
  • AstraZeneca PLC

The driving force behind the need for rapid reporting of microbiological test results is the clinical relevance in a time of financial austerity, a time when cost and health care effectiveness to the patient and diagnostician looms ever larger, and where after-the-fact results at high expen

  • Healthcare
  • Infectious Disease
  • Pathology
  • Australasia
  • Baltics

The driving force behind the need for rapid reporting of microbiological test results is the clinical relevance in a time of financial austerity, a time when cost and health care effectiveness to the patient and diagnostician looms ever larger, and where after-the-fact results at high expen

  • Healthcare
  • Infectious Disease
  • Pathology
  • Baltics
  • Northern Europe

The driving force behind the need for rapid reporting of microbiological test results is the clinical relevance in a time of financial austerity, a time when cost and health care effectiveness to the patient and diagnostician looms ever larger, and where after-the-fact results at high expen

  • Healthcare
  • Infectious Disease
  • Pathology
  • Baltics
  • Northern Europe

Oriola-KD Oyj (OKDBV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Table of Contents Table of Contents ## List of Tables ## List of Figures ## Oriola-KD Oyj, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 ## Oriola-KD Oyj, Pharmaceuticals &

  • Healthcare
  • Pharmaceutical
  • Baltics
  • Latvia
  • M&A

The driving force behind the need for rapid reporting of microbiological test results is the clinical relevance in a time of financial austerity, a time when cost and health care effectiveness to the patient and diagnostician looms ever larger, and where after-the-fact results at high expen

  • Healthcare
  • Infectious Disease
  • Pathology
  • Baltics
  • Northern Europe